- Product Details
- About This Shop
- Payment & Delivery
Crizotinib is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test
Place of Origin
The recommended dose schedule of crizotinib is 250 mg taken orally twice daily. Continue treatment as long as the patient is deriving clinical benefit from therapy. Crizotinib may be taken with or without food. Capsules should be swallowed whole. If a dose of crizotinib is missed, then it should be taken as soon as the patient remembers unless it is less than 6 hours until the next dose, in which case the patient should not take the missed dose. Patients should not
take 2 doses at the same time to make up for a missed dose.
Each capsule contains 250 mg Crizotinib